Push release MHRA approves GLP –one receptor agonist semaglutide to reduce chance of serious coronary heart issues in obese or overweight adults Semaglutide is the main weight loss drug accepted in the UK being a preventative therapy for those with proven cardiovascular disease enhanced cor